Peptomyc — Series A (estimated) · €11.4M

Peptomyc is a spin-off of VHIO and ICREA developing Omomyc-based peptide therapies against MYC-driven cancers. It closed an €11.4M equity round led by the Italian fund AurorA Science to take its lead candidate OMO-103 into a Phase I clinical trial. Existing investors Alta Life Sciences and HealthEquity returned, and CDTI Innvierte and business angels joined.

LeadAurorA Science RoundSeries A (estimated) Announced16 Dec 2020 CityBarcelona SectorHealthtech & Bio · Biotech / Oncology Source V

Something wrong? Suggest a correction →